Literature DB >> 19261248

Improving survival in myelodysplastic syndromes.

Guillermo Garcia-Manero.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19261248     DOI： 10.1016/S1470-2045(09)70048-8

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

Authors:  Lewis R Silverman; Pierre Fenaux; Ghulam J Mufti; Valeria Santini; Eva Hellström-Lindberg; Norbert Gattermann; Guillermo Sanz; Alan F List; Steven D Gore; John F Seymour
Journal:  Cancer       Date:  2011-01-10       Impact factor: 6.860

2.  Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*.

Authors:  Valeria Santini; Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Lewis R Silverman; Alan List; Steven D Gore; John F Seymour; Jay Backstrom; Charles L Beach
Journal:  Eur J Haematol       Date:  2010-04-12       Impact factor: 2.997
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.